Ganga Pharmaceuticals (539680) H1 26/27 earnings summary
Event summary combining transcript, slides, and related documents.
H1 26/27 earnings summary
2 Nov, 2026Executive summary
Unaudited H1 results for the half year ended September 30, 2026, were approved by the Board on November 2, 2026; auditors issued a limited review report.
Financial highlights
Revenue from operations was Rs 141.63 lakh versus Rs 136.65 lakh in H1 FY25; total income was Rs 155.27 lakh.
Profit before tax was Rs 2.52 lakh versus Rs 3.35 lakh in H1 FY25; total expenses were Rs 152.76 lakh versus Rs 144.16 lakh.
Net profit was Rs 1.86 lakh versus Rs 5.50 lakh in H1 FY25; other income was Rs 13.64 lakh versus Rs 14.80 lakh.
Segment performance
Operations were in one business segment: Ayurveda; segment information was therefore not required under AS 17.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Ganga Pharmaceuticals
- Profit rose as revenue stayed nearly flat; IPO funding supported the core Ayurveda business.539680
H2 15/16 - FY17 profit rose as Ayurveda product development and distribution remained central priorities.539680H2 16/17
- Revenue and profit improved as Ayurvedic product and distribution expansion remained central.539680H2 18/19
- FY18 profit rose as Ayurveda product and distribution plans advanced amid industry risks.539680H2 17/18
- Revenue declined, but profit edged up as COVID-19 disrupted FY20 operations.539680H2 19/20
- Pandemic disruption cut revenue and earnings as Ayurveda-focused growth plans advanced.539680H2 20/21
- Revenue and profit rose in FY22 despite macro headwinds; no dividend was recommended.539680H2 21/22
- FY23 income and profit edged higher as Ayurveda growth plans met industry and macro risks.539680H2 22/23
- FY26 revenue and profit rose, equity increased, and auditors gave an unmodified opinion.539680H2 25/26